LinXis technology discussed in Expert Opinion on Drug Delivery
LinXis technology and lead product highlightedJuly 22, 2019
Compared to the antibody and drug components of an ADC, the linker part has been somewhat neglected. However, many of the recent failures in the ADC field suggest that a stable linker may be the key to unlock the therapeutic window of cancer-directed ADCs. Next to being a stable glue between drug and antibody, the ideal linker should also improve ADC manufacturability, as only robust and cost-effective manufacturing processes will place these inherently complex therapeutics within the reach of patients in need.
In our recent paper in the peer-reviewed journal ‘Expert Opinion on Drug Delivery’, we discuss how Lx® linker technology meets these requirements, with our lead product LxC-001 at center stage. Please find the paper on the journal website.